Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021

  • ID: 4201974
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AADi
  • Arena Pharmaceuticals
  • Berlin Cures
  • Eiger BioPharmaceuticals
  • Merck
  • PhaseBio Pharmaceuticals
  • MORE
About Pulmonary Arterial Hypertension (PAH) Drugs
PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult.

The analysts forecast the global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market size, the report considers the MoA and the RoA.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Pulmonary Arterial Hypertension Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Actelion Pharmaceuticals
- DAIICHI SANKYO
- GlaxoSmithKline
- Novartis
- United Therapeutics

Other prominent vendors
- AADi
- Actelion Pharmaceuticals
- Aires Pharmaceuticals
- Arena Pharmaceuticals
- Asklepion Pharmaceuticals
- AstraZeneca
- Bayer Healthcare
- Berlin Cures
- BIAL
- DEKA Research & Development
- Dong- A ST
- Eiger BioPharmaceuticals
- Gilead Sciences
- Lung Biotechnology
- Merck
- Northern Therapeutics
- Pfizer
- PhaseBio Pharmaceuticals
- Radikal Therapeutics
- Reata Pharmaceuticals
- SteadyMed Therapeutics
- Velo Bio

Market drivers
- New disease-modifying therapies
- For a full, detailed list, view the full report

Market challenges
- Patent expiries of major drugs

- For a full, detailed list, view the full report

Market trends
- Increased focus on combination therapies
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AADi
  • Arena Pharmaceuticals
  • Berlin Cures
  • Eiger BioPharmaceuticals
  • Merck
  • PhaseBio Pharmaceuticals
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of PAH

PART 06: Pipeline analysis

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by route of administration (RoA)
  • Oral administration
  • Injectables
  • Inhalation
PART 09: Market segmentation by mechanism of action (MoA)
  • ERAs
  • Prostacyclin analogs
  • PDE inhibitors
  • sGC stimulators
PART 10: Geographical segmentation
  • PAH market in Americas
  • PAH market in EMEA
  • PAH market in APAC
PART 11: Decision framework

PART 12: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 13: Market trends
  • Increased focus on combination therapies
  • Increase in awareness
  • Intense competition among vendors
PART 14: Vendor landscape
  • Competitive scenario
PART 15: Key vendor analysis
  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Categorization of PAH
Exhibit 02: Pipeline overview
Exhibit 03: Pipeline landscape
Exhibit 04: Global PAH drugs market snapshot
Exhibit 05: Global PAH drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of global PAH market 2016
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by RoA
Exhibit 09: Global PAH drugs market segmentation by RoA 2016
Exhibit 10: Global PAH drugs market segmentation by MoA
Exhibit 11: Global ERAs market 2016-2021 ($ millions)
Exhibit 12: Global prostacyclin analogs market 2016-2021 ($ millions)
Exhibit 13: Global PDE inhibitors market 2016-2021 ($ millions)
Exhibit 14: Global PAH sGC stimulators market 2016-2021 ($ million)
Exhibit 15: Geographical segmentation of PAH drugs market
Exhibit 16: PAH drugs market revenue by geography 2016-2021 (%)
Exhibit 17: Market scenario in Americas
Exhibit 18: PAH drugs market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: PAH drugs market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: PAH drugs market in APAC 2016-2021 ($ millions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of challenges
Exhibit 25: Competitive structure analysis of global PAH drugs market 2016
Exhibit 26: Competitive analysis of global PAH drugs market 2016
Exhibit 27: Actelion Pharmaceuticals: Key highlights
Exhibit 28: Actelion Pharmaceuticals: Strength assessment
Exhibit 29: Actelion Pharmaceuticals: Strategy assessment
Exhibit 30: Actelion Pharmaceuticals: Opportunity assessment
Exhibit 31: DAIICHI SANKYO: Key highlights
Exhibit 32: DAIICHI SANKYO: Strength assessment
Exhibit 33: DAIICHI SANKYO: Strategy assessment
Exhibit 34: DAIICHI SANKYO: Opportunity assessment
Exhibit 35: GlaxoSmithKline: Key highlights
Exhibit 36: GlaxoSmithKline: Strength assessment
Exhibit 37: GlaxoSmithKline: Strategy assessment
Exhibit 38: GlaxoSmithKline: Opportunity assessment
Exhibit 39: Novartis: Key highlights
Exhibit 40: Novartis: Strength assessment
Exhibit 41: Novartis: Strategy assessment
Exhibit 42: Novartis: Opportunity assessment
Exhibit 43: United Therapeutics: Key highlights
Exhibit 44: United Therapeutics: Strength assessment
Exhibit 45: United Therapeutics: Strategy assessment
Exhibit 46: United Therapeutics: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AADi
  • Arena Pharmaceuticals
  • Berlin Cures
  • Eiger BioPharmaceuticals
  • Merck
  • PhaseBio Pharmaceuticals
  • MORE
New Report Released: – Global Pulmonary Arterial Hypertension Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global pulmonary arterial hypertension drugs market: Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis, and United Therapeutics.

Other Prominent Vendors in the market are: AADi, Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, Asklepion Pharmaceuticals, AstraZeneca, Bayer Healthcare, Berlin Cures, BIAL, DEKA Research & Development, Dong- A ST, Eiger BioPharmaceuticals, Gilead Sciences, Lung Biotechnology, Merck, Northern Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed Therapeutics, and Velo Bio.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increased focus on combination therapies. The PAH treatment is shifting toward the use of combination therapies that employ two or more drugs. A combination therapy with separate agents or a fixed dose of combination pill offers the maximum potential to lower blood pressure. The treatment is also aimed at targeting various disease mechanisms that may result in better outcome.”

According to the report, one of the major drivers for this market is new disease-modifying therapies. Many new agents in the market are expected to show promising results in terms of efficacy as they target the receptors involved in the progression of PAH. For instance, OPSUMIT launched in 2013 in the US is an ERA, which mediates vasoconstriction, hypertrophy, and inflammation. The drug prevents the binding of endothelin (ET-1) to both endothelin receptors, ET-A and ET-B, resulting in decreased hypertension.

Further, the report states that one of the major factors hindering the growth of this market is patent expiries of major drugs. Patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in the sale of the drug. The introduction of low-cost generics, as a consequence to patent expiries, results in the rapid sales decline of the branded drugs, leading to reduced value for the overall market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Actelion Pharmaceuticals
  • DAIICHI SANKYO
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics
  • AADi
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Asklepion Pharmaceuticals
  • AstraZenec
  • Bayer Healthcare
  • Berlin Cures
  • BIAL
  • DEKA Research & Development
  • Dong- A ST
  • Eiger BioPharmaceuticals
  • Gilead Sciences
  • Lung Biotechnology
  • Merck
  • Northern Therapeutics
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Radikal Therapeutics
  • Reata Pharmaceuticals
  • SteadyMed Therapeutics
  • Velo Bio
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll